Introduction
Diabetic retinopathy (DR) is caused by alterations of the retinal microvasculature leading to the breakdown of the blood-retina barrier and pathological angiogenesis [1] [2] [3] [4] [5] [6] . In diabetic retinopathy (DR) and other angiogenesis-associated diseases, increased levels of cytokines, inflammatory cells, and angiogenic factors are present [7] [8] [9] [10] [11] [12] . Therefore, the cytokines interleukin 4 (IL-4), IL-10 and IL-12 are speculated to play an important role in the development and the progression of DR.
Numerous defects that develop in retinas as a result of diabetes are consistent with a diabetes-induced inflammatory response in that tissue. These inflammatory changes are important in the pathogenesis of DR [8] . During the inflammatory reaction, anti-inflammatory cytokines are also produced and tend to modulate the inflammatory process. However, little information is available regarding the potential role of anti-inflammatory cytokines in proliferative diabetic retinopathy (PDR). IL-10 is an anti-inflammatory cytokine with potent deactivating properties on macrophages. In addition, antitumoral effects of IL-10 have been associated with its ability to prevent angiogenesis associated with tumour growth. Furthermore, it has been recently demonstrated that its anti-angiogenic effect is associated with the down-regulation of vascular endothelial growth factor expression [13] . The rs1800896 polymorphism in the promoter region of the IL-10 gene was reported to affect the expression of IL-10 [14] . Additionally, the rs1800896 polymorphism was reported to affect the serum IL-10 level [15] . Moreover, the IL-10 was implicated in the pathogenesis of PDR [13, 16, 17] .
IL-4 is a pleiotropic cytokine produced by Th2-cells, eosinophils and mast cells. It mediates the humoral immune response and exerts anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and by changing the expression profile of macrophages. The role of IL-4 in the development and progression of complex diseases has been studied using single nucleotide polymorphisms (SNPs) in the IL-4 gene which are associated with IL-4 expression. The rare alleles of these polymorphisms were found to be associated with high IL-4 expression, elevated total serum IgE, increased severity and progression of asthma, IgA nephropathy, certain carcinomas, late onset disease in AIDS (however, not in all studies) and Th1-type diseases, such as multiple sclerosis and rheumatoid arthritis [18] .
A functional IL-4 gene polymorphism, which is characterized by a C to T substitution in the promoter region of the IL-4 gene (rs2243250), has been identified [19, 20] and has been shown to increase IL-4 transcriptional activity [18] , but it has not been studied among patients with proliferative diabetic retinopathy (PDR) yet. Several studies, however, support the pathogenic role of IL-4 in angiogenesis [21] .
IL-12 has a diverse function in the immune response and strong effects in determining the nature of the immune response that is to be mounted. IL-12 influences activated T cells to secrete cytokines typical of inflammatory immune response. It is now clear that genetic variants of IL12B contribute to susceptibility of various diseases that have in common an underlying immune dysregulation. These diseases include dermatitis, infections (cerebral malaria, tuberculosis, and leprosy), asthma, and, most recently, steroidsensitive childhood nephrotic syndrome [22] . IL-12 is composed of two subunits, a light chain of 35 kDa, p35, and a heavy chain of 40 kDa, p40, which are encoded by two separate genes, the IL12A gene on chromosome 3 and the IL12B gene on chromosome 5, respectively [23, 24] . Many cell types express the p35 chain, while the p40 subunit is expressed principally by activated macrophages and B cells [23] . The major effects of IL12B have been attributable to polymorphisms in the 3′UTR, or in its promoter, or from a combination of both [22] . Several single nucleotide polymorphisms have recently been identified in IL12B gene [23, 25] , of which the A allele of the 3' UTR single nucleotide polymorphism (rs3212227) showed strong linkage disequilibrium with the type 1 diabetes susceptibility locus IDDM18 in Australian and British diabetes families [26] . Moreover, the IL-12 has recently been reported to be involved in the pathogenesis of DR in type 1 diabetes [12] , but it has not been studied among patients with proliferative diabetic retinopathy yet.
In the present study we investigated the possible association between the rs2243250 polymorphism of the IL-4 gene, the rs1800896 polymorphism of the IL-10 gene, and rs3212227 polymorphism of the IL12B gene and PDR among Caucasians with type 2 diabetes.
Experimental Procedures
376 unrelated Caucasians with type 2 diabetes mellitus with a defined ophthalmologic status were enrolled in this cross-sectional study (from Ljubljana, Slovenia and Tuzla, Bosnia and Herzegovina). Patients were classified as having type 2 diabetes according to the current American Diabetes Association criteria [The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997]. Fundus examination was performed by a senior ophthalmologist (MGP) after pupil dilatation (tropicamide and phenylephrine 2.5%) using slit-lamp biomicroscopy with non-contact lens, and was electronically documented with a 50°-angle fundus camera (Topcon-TRC 40-IX; Tokyo, Japan). The stage of diabetic retinopathy was determined according to the Early Treatment Diabetic Retinopathy Study Research Group retinopathy severity scale. The study group consisted of 189 subjects with proliferative diabetic retinopathy (new vessel proliferation at the optic disc or elsewhere in the retina). The control group consisted of 187 subjects with type 2 diabetes of the duration of more than 10 years who had no clinical signs of proliferative diabetic retinopathy. Moreover, 103 healthy subjects (without diabetes) were enrolled to compare the genotype distribution between diabetics and nondiabetics.
To avoid the confounding effect of impaired kidney function, the patients with overt nephropathy (albumin excretion rate >200 μg/min or greater than 300 mg/day in at least two out of three consecutive overnight urine samples) were not enrolled. The study was approved by the national medical ethics committee. After an informed consent for the participation in the study had been obtained, a detailed interview was made. The rs2243250 polymorphism of the IL-4 gene was evaluated by PCR, using primers: sense: 5`-TAAACTTGGGAGAACATGGT -3`, antisense: 5`-TGGGGAAAGATAGAGTAATA -3`. The cycling conditions were: 1 cycle of 94ºC for 5 min, 94ºC for 55 s, 51ºC for 1 min, 72ºC 50 s; 30 cycles and 72ºC 5 min. PCR products of 343 bp were digested with Eco 471 (Fermentas) into three fragments (198 bp, 177 and18 bp). The fragments of 177 and 18 bp represented the C allele whereas fragment 195 represented the A allele. The products were separated by electrophoresis on a 3% agarose gel and visualized by Syber green staining [19] . The rs1800896 polymorphism of the IL-10 gene was evaluated by (ARMS) PCR method, using primers: generic primer antisense: 5`-CAGTGCCAACTGAGAATTGG -3`, primer G sense: 5`-CTACTAAGGCTTCTTTGGGAG-3, primer A sense 5`-ACTACTAAGGCTTCTTTGGGAA -3. The cycling conditions were: 1 cycle of 95 ºC for 1 min, 95ºC for 15 s, 65ºC for 50 s, 72ºC 40 s -10 cycles; 95ºC for 20 s, 59ºC for 50 s, 72ºC 50 s -20 cycles. PCR products were monitored by electophoresis on a 2% agarose gel containing Syber green. PCR product size was 258 bp [27] .
The rs3212227 polymorphism of the 3' untranslated region (3' UTR) of the IL12B gene was evaluated with the polymerase chain reaction (PCR) based restriction fragment length polymorphism (RFLP) assay for the rs3212227 as described previously [28] .
Data are expressed as means ± standard deviations or frequencies (percentages). The chi-square test was used to compare discrete variables. Continuous clinical data were compared by an unpaired Student's t test. Multiple logistic regression analysis was performed for the evaluation of the independent effect of genotypes on PDR development, adjusted for the presence of insulin therapy, age of diabetes onset and duration of diabetes. A P<0.05 was considered statistically significant.
Assuming the significance level of 0.05, frequency of risk allele of 0.21 in the control (non-PDR) group and of 0.31 in the PDR group, we calculated the power of our study sample (189 PDR cases, 187 controls-diabetics without PDR ) to be 84%.
A statistical analysis was performed using the SPSS program for Windows version 17 (SPSS Inc. Illinois).
Results
The characteristics of patients studied are summarized in Table 1 . The frequency of IL-10 (rs1800896), IL-4 (rs2243250) and IL-12 (rs3212227) polymorphisms are shown in Univariate analysis did not demonstrate an association between the risk genotypes of the tested polymorphisms and PDR (Table 2) . Logistic regression analysis, however, demonstrated the IL-10 rs1800896 GG genotype as an independent risk factor for PDR (Table 3) , whereas the IL-4 rs2243250 TT and IL-12 rs3212227 AA genotypes were not independent risk factors for PDR (Table 3) 
Discussion
This study suggests that IL-10 rs1800896 GG genotype is an independent risk factor for PDR in Caucasians with type 2 diabetes, whereas the IL-4 rs2243250 and the IL12B rs3212227 polymorphisms are not independent risk factors for PDR. According to our best knowledge, this is the first study with the IL-10 rs1800896 polymorphism in PDR. Previously, the rs1800896 polymorphism was reported to influence the risk of nephropathy in patients with diabetes type 2 [29] . We speculate that the effect of the IL-10 rs1800896 polymorphism is due to IL-10 expression, since the rs1800896 polymorphism of the IL-10 was reported to affect the vitreous IL-10 level [15] . Namely, the GG genotype of the rs1800896 polymorphism of the IL-10 gene was reported to be associated with high IL-10 production, the GA genotype of the rs1800896 polymorphism of the IL-10 gene with intermediate production, and the AA genotype of the rs1800896 polymorphism of the IL-10 gene with low IL-10 production [15] . Moreover, the increased serum concentration of IL-10 was reported to be associated with the progression of diabetic nephropathy [30] . In few other studies, however, it was reported that low levels of circulating IL-10 are involved in the pathogenesis of PDR [13, 16, 17] Ozturk et al. did not find any statistically significant differences in serum IL-10 levels among diabetics with PDR, non-proliferative DR, and diabetics without DR [17] . Moreover, Dace et al. have recently demonstrated that IL-10 promotes retinal neovascularization in a mouse model of oxygen-induced retinopathy [31] . Intraocular neovascularization, as characterized by abnormal retinal or choroidal angiogenesis, is a major cause of decreased vision in patients with PDR [31] . Since the IL-4 was reported to affect the angiogenesis, IL-4 might be implicated in the pathogenesis of PDR. Volpert et al. demonstrated that IL-4 is a potent inhibitor of angiogenesis in vivo when introduced locally as well as when injected systemically [21] . Lee et al., however, reported that IL-4 significantly enhanced the tube formation in the absence of VEGF or bFGF [32] . This finding suggests that IL-4 has angiogenic activity under certain conditions. Indeed, there are reports that support the pro-angiogenic function of IL-4 [33, 34] . However, most of these results are "in vitro" observations and were carried out in the absence of VEGF or bFGF, whereas most of the reports about the "in vivo" effect of IL-4 support the antiangiogenic role of IL-4 [21, 35, 36] . To our best knowledge, our study is the first to analyse the IL-4 rs2243250 polymorphism in subjects with PDR. In the promoter region of the IL-4 gene, a single nucleotide polymorphism (rs2243250) affects gene transcription. The substitution of C by T in position -590 of the IL-4 gene causes reduced cytokine expression while the TT form upregulates the production of this cytokine [37] . In this study, however, we failed to demonstrate an association. The expression of cytokines is also affected by local factors, thus our finding that the IL-4 rs2243250 polymorphism is not associated with PDR does not necessarily argue against the role of this polymorphism in the pathogenesis of PDR.
It is now clear that genetic variants of IL12B contribute to the susceptibility of various diseases that have in common an underlying immune dysregulation [22] . Several single nucleotide polymorphisms have recently been identified in the IL12B gene [23, 25] , of which the A allele of the 3' UTR single nucleotide polymorphism (rs3212227) showed strong linkage disequilibrium with the type 1 diabetes susceptibility locus IDDM18 in Australian and British diabetes families [26] . The 3'UTR region is able to influence the amount of translated protein by several mechanisms, including effects on mRNA stability as well as on transcriptional activity [38] . IL-12 was reported to inhibit angiogenesis in an "in vivo" mouse model of corneal neovascularization [39] . Rothe et al. have emphasized the pathogeneic role of the IL-12 in insulin-dependent diabetes mellitus of the non-obese diabetic mice. Moreover, IL-12 proved to be a potent inhibitor of angiogenesis and may also contribute to the pathogenesis of diabetic retinopathy more likely as a part of the consecutive immunological response mechanisms rather than a predisposing factor [40] . Moreover, the IL-12 that was implicated in the pathogenesis of DR in type 1 diabetes [12] was not associated with PDR in Caucasians with type 2 diabetes in our study. Further studies comparing vitreous and serum levels of these interleukins and their polymorphisms are needed to provide a better understanding of the role of IL-4 and IL-12 in PDR.
The multivariate analysis demonstrated that IL-10 rs1800896 GG genotype, diabetes duration, insulin therapy, and age of diabetes onset were associated with PDR, whereas the IL-4 rs2243250 TT genotype and the IL-12 rs3212227 AA genotype were not independent risk factors for PDR. Our results increase the knowledge of genetic risk factors for developing PDR in type 2 diabetes. It seems, however, that the PDR cases had more severe form of type 2 diabetes in comparison with diabetics without PDR, i.e. PDR cases had earlier onset of diabetes, longer duration of type 2 diabetes and higher incidence of insulin therapy compared to the diabetics without PDR. Moreover, insulin therapy was significantly associated with PDR independent of the tested gene polymorphisms. This finding suggests the existence of other factors such as differences in the ability of insulin secretion, or differences in the frequency of episodes of hypoglycemia, or adverse events associated with insulin therapy (hypoglycemia, worsening diabetic retinopathy if HbA 1c decreases rapidly) [41] . Moreover, our study demonstrated the difference in genotype distribution between diabetics and subjects without diabetes in IL-12 gene rs3212227 polymorphism. Our finding is in accordance with the study reported by Davoodi-Semiromi et al. [42] . They reported the IL-12p40 to be associated with type 1 diabetes in Caucasian-American families.
A limitation of the present study is the relatively low number of PDR subjects and controls (diabetics without PDR). Further studies enrolling larger numbers of patients from different populations are needed to confirm our findings. Namely, genetic association studies are prone to beta statistical error and population-specific genotype effects, all of which make the results difficult to reproduce. In fact, the calculated power of our study for the IL-10 rs1800896 polymorphism was 84% taking into account the size of our study sample, and the frequencies of risk allele in PDR cases and diabetics without PDR.
In conclusion, our findings suggest that the genetic variations at the IL-10 promoter gene might be a genetic risk factor for PDR in Caucasians with type 2 diabetes. Additionally, larger studies on this issue are needed to confirm our findings. 
